Resultados de investigación

Presentación de la sessión Plenaria 4 a cargo de Carles Llop, Director del Congreso. Moderadores de la sesión: Mosé Ricci (Univesidad de Trento) y Manuel Gausa (Universidad de Génova). SAB) y Miquel Martí: Ponentes: Patrizia Gabellii; Arturo Lanzani; Maria Chiara Tosi. (Ponencias en italiano con traducción subtitulada al castellano), Objectius de Desenvolupament Sostenible::11 - Ciutats i Comunitats Sostenibles

Més informació a: / Más información en: https://segues.upc.edu/es/jornadas-segues/segues20

Més informació a: / Más información en: https://segues.upc.edu/es/jornadas-segues/segues20

El Foment Vilanoví organitza el primer Tribuna en format telemàtic amb la col·laboració de l'EPSEVG amb la Dra. Clara Prats. Clara Prats, llicenciada en Física per la Universitat de Barcelona i doctora en Física Aplicada i Simulació en Ciències per la Universitat Politècnica de Catalunya (UPC). Actualment és professora agregada de la UPC. Investigadora del grup de Biologia Computacional i Sistemes Complexos de la UPC, i responsable de models computacionals al Centre de Medicina Comparativa i Bioimatge de l’Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP). La seva línia de recerca se centra en l’ús de la modelització computacional per a l’estudi de malalties infeccioses, principalment la tuberculosi, però també la malària, la malaltia del Chagas i, els últims mesos, la COVID-19. En col·laboració amb el Diari de Vilanova es va crear Tribuna Vilanova, un espai on dialogar amb persones d’interès rellevant a Vilanova i la Geltrú i Catalunya de diferents àmbits d’activitat: social, jurídic, cívic, artístic, literari, entre d'altres.

Postprint (author's final draft)

Conjunt editat de fragments sonors de 40 gravacions de regal enviades pel sant de Francesc Daumal el dia 2 d'abril de 2020., La simultània embolcallada per a regal és una obra artística basada en 40 paisatges sonors reals provinents de tot el món, que s’han gravat simultàniament a migdia del dia del meu sant, el 2 d’abril del 2020, en plena pandèmia. La gravació final, de 3 minuts d’extensió en total, té 40 talls sonors, de 4,5 segons cadascún, empalmats de forma consecutiva, respectant l’ordre en que es vàren recepcionar les gravacions originals. Els autors han cedit els seus drets per a poder fer aquest compendi, en el que ha participat molt activament el tècnic de so Hèctor Balart Armengol, compatibilitzant els diferents llenguatges de cada deriva sonora, i fent l’elecció aleatòria dels seus valors estètics més representatius. Aquesta obra s’hapresentat com a primicia el 14 d’octubre 2020, a la Biennal del Pensament de l’Ajuntament de Barcelona, per a la taula rodona Sons, Sorolls, Silencis. Cap a una ecología acústica urbana en l’era digital. Participants: Francesc Daumal i Domènech, Fernando Valdés, Rosa María Alsina, Antonio de Clemente, Vicent Matamoros, Laura Puig, Oriol Server Yerga, Carlos Gómez Caballero, Valentin Martín Fanjul, Belen Casla Herguedas, Pedro Montesinos, Ebe Giovannini, Julia Angiolini, Pedro Alcalde, Riccardo Chinni, Sandra del Rio Bonnin, Marta Monzón, Eduard Puig Solé, Luis Gerald Montero, David Pérez Vallejo, Fernando J. Elizondo-Garza, Miguel Molina-Alarcón, Alicia González Escamilla, José Nocito, Josep Manuel Berenguer Alarcón, Josep Cerdà, Gabriel de Toledo Piza, Jerónimo Vida, José Luís de Carles, Estefanía Aimar, Uli Marchsteiner, Luis Paulino Salas, Ricardo Atienza, Ivana Rossell, Leonel de la Pava, Enric Mir, Cesc Cels i López, Rosa Mª Cibrián Ortiz de Anda., La simultánea envuelta para regalo, es una obra artística basada en 40 paisajes sonoros reales provenientes de todo el mundo, que se han grabado simultáneamente a mediodía del día de mi santo, el 2 de abril del 2020, en plena pandemia. La grabación final, de 3 minutos de extensión en total, contiene 40 cortes sonoros, de 4,5 segundos cada uno, empalmados de forma consecutiva, respetando el orden en que se recepcionaron las grabaciones originales. Los autores han cedido sus derechos para poder hacer este compendio, en el que ha participado muy activamente el técnico de sonido Héctor Balart Armengol, compatibilizando los diferentes lenguajes de cada deriva sonora, y realizando la elección aleatoria de sus valores estéticos más representativos. Esta obra se presentó como primicia el 14 de octubre del 2020 en la Bienal del Pensamiento del Ayuntamiento de Barcelona, para la mesa redonda Sonidos, Ruidos, Silencios. Hacia una ecología acústica urbana en la era digital. Participantes: Francesc Daumal i Domènech, Fernando Valdés, Rosa María Alsina, Antonio de Clemente, Vicent Matamoros, Laura Puig, Oriol Server Yerga, Carlos Gómez Caballero, Valentin Martín Fanjul, Belen Casla Herguedas, Pedro Montesinos, Ebe Giovannini, Julia Angiolini, Pedro Alcalde, Riccardo Chinni, Sandra del Rio Bonnin, Marta Monzón, Eduard Puig Solé, Luis Gerald Montero, David Pérez Vallejo, Fernando J. Elizondo-Garza, Miguel Molina-Alarcón, Alicia González Escamilla, José Nocito, Josep Manuel Berenguer Alarcón, Josep Cerdà, Gabriel de Toledo Piza, Jerónimo Vida, José Luís de Carles, Estefanía Aimar, Uli Marchsteiner, Luis Paulino Salas, Ricardo Atienza, Ivana Rossell, Leonel de la Pava, Enric Mir, Cesc Cels i López, Rosa Mª Cibrián Ortiz de Anda.

This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated with olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six cycles of olaratumab (20 mg/kg, cycles 1-2; 15 mg/kg, cycles 3-7) plus doxorubicin (75 mg/m2 on day 1). CTCs, platelet-derived growth factor receptors (PDGFR), and PDGF ligand expression in tumor tissue pre- and post-olaratumab monotherapy were evaluated. Antitumor activity, safety, pharmacokinetics, and PET/biomarker association with clinical outcome were assessed. Of 51 treated patients, 35, 43, and 37 were evaluable for CTC enumeration, PDGFRs, and PDGF ligand expression, respectively. An increase in CTCs at cycle 1 day 8 was observed, followed by a significant reduction by cycle 3 day 1 or 30-day follow-up. Decrease in CTC counts after olaratumab monotherapy was higher in patients with disease control than without disease control (57.9% vs. 31.2%). Baseline IHC expression was positive in most patients for PDGFRα [n = 31 (72.1%)] and PDGFRβ [n = 36 (83.7%)]. Similar rates were observed post-olaratumab monotherapy [PDGFRα, n = 30 (69.8%); PDGFRβ, n = 33 (76.7%)]. Eleven patients (29.7%) showed a 30% reduction by RT-PCR in PDGFRα at cycle 2. PDGFR expression and PET response showed no correlation with clinical outcome. Safety and pharmacokinetic profiles were consistent with previous reports. This study, the first to use a validated method for CTC detection, confirms that CTC enumeration in STS is feasible. However, no correlation was observed between PDGFRα expression and clinical outcome., Si

Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system metastases. In this phase I study, we assessed the effects of normal renal function (NRF) and severe renal impairment (SRI) on the pharmacokinetics (PK) of osimertinib in patients with solid tumors. Part A: patients with NRF (creatinine clearance [CrCL] ≥90 mL/min), and SRI, (CrCL <30 mL/min), received a single 80-mg oral dose of osimertinib and standard PK measures were assessed. Part B: patients with SRI were treated for 3 months to obtain safety data, if deemed clinically appropriate. The geometric mean osimertinib plasma concentrations were higher in patients with SRI (n = 7) vs NRF (n = 8) and were highly variable. Osimertinib exposure based on Cmax and area under the plasma concentration-time curve, was 1.19-fold (90% CI: 0.6, 2.0) and 1.85-fold (90% CI: 0.9, 3.6), respectively, higher for patients with SRI vs patients with NRF, with no clear correlation between CrCL and exposure. No new safety signals were identified after 12 weeks of osimertinib 80 mg continuous dosing. PK parameters pooled across this study and other phase I, II, and III osimertinib clinical studies (exploratory population PK analysis), showed minimal correlation between CrCL and total clearance. In conclusion, no dose adjustment is required for osimertinib for patients with SRI., Si

CheckMate 171 (NCT02409368) is an open-label, multicentre, phase 2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer (NSCLC), conducted as part of a post-approval commitment to the European Medicines Agency (EMA). We report outcomes from this trial. Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2 and disease progression during/after ≥1 systemic treatment (≥1 being platinum-based chemotherapy) for advanced or metastatic disease were treated with nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxicity. The primary end-point was incidence of grade 3-4 treatment-related select adverse events (AEs). Other end-points included overall survival (OS) and safety. Of 811 patients treated, 103 had ECOG PS 2; 278 were aged ≥70 years and 125 were ≥75 years of age. Minimum follow-up was ~18 months. Safety was similar across populations; the most frequent grade 3-4 treatment-related select AEs in all treated patients were diarrhoea (1%), increased alanine aminotransferase (ALT, 1%), pneumonitis (0.7%), colitis (0.6%) and increased aspartate aminotransferase (AST, 0.5%). Median OS was similar in all treated patients and those aged ≥70 and ≥75: 10.0 months, 10.0 months and 11.2 months, respectively. Median OS was 5.2 months in patients with ECOG PS 2. These results suggest that nivolumab is well tolerated and active in patients with advanced, relapsed squamous NSCLC, including the elderly, with OS outcomes consistent with phase 3 data. In patients with ECOG PS 2, nivolumab had similar tolerability, but outcomes were worse, as expected in this difficult-to-treat, poor prognosis population. NCT02409368., Si